Moreover, this inhibition is specific for TRIB2 because of the lack of equivalent Cys residues in other pseudokinases, including TRIB1, TRIB3, and STK40, indicating the convenience of this therapeutic approach for tumours in which high levels of TRIB2 correlates with worst prognosis. This evidence concerns the gene TRIB2 and neoplasm.